Latest News and Press Releases

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative,...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative,...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and...

-  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m....

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative,...

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company’s current operating plan,...

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and...

-  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...